gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Multimerin 1

p155, Multimerin, multimerin 1, MMRN1
Multimerin is a massive, soluble protein found in platelets and in the endothelium of blood vessels. It is comprised of subunits linked by interchain disulfide bonds to form large, variably sized homomultimers. Multimerin is a factor V/Va-binding protein and may function as a carrier protein for platelet factor V. It may also have functions as an extracellular matrix or adhesive protein. Recently, patients with an unusual autosomal-dominant bleeding disorder (factor V Quebec) were found to have a deficiency of platelet multimerin. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: p140, HAD, CAN, OUT, fibrillin-1
Papers on p155
[Juvenile dermatomyositis and new autoantibodies: Cases and review].
Belot et al., Marseille, France. In Arch Pediatr, Dec 2015
For these patients, the immunologic study found one patient positive for the MDA5 antibody (or CADM 140), one positive for the TIF1γ antibody (or p155/140), and two patients positive for the NXP2 antibody (or p140/MJ).
Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis.
Childhood Myositis Heterogeneity Study Group et al., Utrecht, Netherlands. In Arthritis Rheumatol, Nov 2015
Furthermore, a severe illness onset was associated with chronic compared to monocyclic or polycyclic courses (M-OR 2.1 and 2.6), while anti-p155/140 autoantibodies were associated with chronic or polycyclic courses compared to monocyclic (M-OR 3.9 and 2.3).
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Chan et al., Kitakyūshū, Japan. In Clin Rev Allergy Immunol, Oct 2015
Antibodies to transcription intermediary factor 1γ/α (TIF1γ/α, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD.
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Walter et al., Seattle, United States. In Clin Cancer Res, Aug 2015
PURPOSE: Exploratory gene expression array analyses suggested multimerin-1 (MMRN1) to be a predictive biomarker in acute myelogenous leukemia (AML).
Exosomal protein interactors as emerging therapeutic targets in urothelial bladder cancer.
Agrawal et al., New Delhi, India. In J Egypt Natl Canc Inst, Jun 2015
Proteins in the 9 top-ranked pathways included CTNNA1 (alpha-catenin), CTNNB1 (beta-catenin), VSAP, ITGA4, PAK1, DDR1, CDC42, RHOA, NRAS, RHO, PIK3AR1, MLC1, MMRN1, and CTTNBP2 and network analysis revealed 10 important hub proteins and identified inferred interactor NF2.
Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
Chagai et al., Tel Aviv-Yafo, Israel. In Clin Rheumatol, May 2015
One patient developed CADM associated with the anti-p155/140 antibody, a year after completing chemotherapy for non-seminomatous germ cell tumor.
Four Copies of SNCA Responsible for Autosomal Dominant Parkinson's Disease in Two Italian Siblings.
Gambardella et al., Italy. In Parkinsons Dis, 2014
Genetic analysis of siblings showed for the first time a 351 Kb triplication containing SNCA gene along with 6 exons of MMRN1 gene in 4q22.1 and a duplication of 1,29 Mb of a genomic region flanking the triplication.
Immunoprecipitation: Western blot for proteins of low abundance.
Targoff et al., Oklahoma City, United States. In Methods Mol Biol, 2014
Recently, immunoprecipitation-blotting helped us characterize a new autoantibody, anti-p155, and to test for the presence of the autoantibody in patient sera to study its clinical associations.
Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.
Senécal et al., Montréal, Canada. In Medicine (baltimore), 2014
Anti-Mi-2, anti-MJ, and anti-p155 autoantibodies were present in 50% of pure DM patients and were restricted to this subset (PPV 100%).
[Auto-immune diseases and cancers. Second part: auto-immune diseases complicating cancers and their treatment].
Hot et al., Lyon, France. In Rev Med Interne, 2014
A combination of detection of antibodies against p155 and TEP-computed tomography may be the best approach to ascertain the presence of occult malignancy in patients with dermatomyositis.
Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis.
Chiang et al., Taipei, Taiwan. In J Microbiol Immunol Infect, 2014
The aim of this study was to assess the presence of anti-p155/140, anti-p140 antibodies, and antiendothelial cells antibodies (AECA) in patients with JDM and to correlate autoantibodies with clinical manifestations.
Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis.
Wang et al., Beijing, China. In Plos One, 2013
For DM patients, results indicated an increased risk of malignancy with older age, male sex, the presence of cutaneous necrosis, elevated ESR (>35 mm/hr), higher CRP levels, or anti-p155 antibody.
New autoantibodies and their clinical associations in juvenile myositis - a systematic review.
Martini et al., In Acta Reumatol Port, 2013
METHODS: A systematic literature search was carried out to identify all studies concerning these novel MSAs (p155/140, p140, CADM-140, SAE and 200/100) in patients with JIIMs.
[Myositis-specific autoantibodies].
Fujimoto, Kanazawa, Japan. In Brain Nerve, 2013
Anti-Mi-2, anti-MDA5 (anti-CADM140), anti-TIF1 (anti-155/140, anti-p155), anti-NXP-2 (anti-MJ), and anti-SAE antibodies are specific for dermatomyositis.
Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1.
Hayward et al., Toronto, Canada. In Thromb Res, 2010
Our data suggest that multimerin 1 supports platelet adhesive functions and thrombus formation, which will be important to verify by generating and testing selective multimerin 1 deficient mice.
Platelet adhesion to multimerin 1 in vitro: influences of platelet membrane receptors, von Willebrand factor and shear.
Hayward et al., Hamilton, Canada. In J Thromb Haemost, 2009
MMRN1 supported the adhesion of activated, but not resting, washed platelets over a wide range of shear rates
Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation.
Hayward et al., Hamilton, Canada. In Thromb Haemost, 2008
Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation.
Location of the multimerin 1 binding site in coagulation factor V: an update.
Hayward et al., Hamilton, Canada. In Thromb Res, 2007
The MMRN1 binding site was located in Factor V.
Analyses of cellular multimerin 1 receptors: in vitro evidence of binding mediated by alphaIIbbeta3 and alphavbeta3.
Hayward et al., Hamilton, Canada. In Thromb Haemost, 2005
MMRN1 is a ligand for alphaIIbbeta3 and alphavbeta3
share on facebooktweetadd +1mail to friends